Dashboard
Manage Tickers

MRKMerck & Co., Inc.

NYSE merck.com


$ 115.95 $ -1.89 (-1.6 %)    

Monday, 09-Sep-2024 10:50:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.37 $ -1.16 (-0.26 %)
DIA $ 408.32 $ 0.99 (0.24 %)
SPY $ 544.37 $ -0.30 (-0.06 %)
TLT $ 99.71 $ 0.33 (0.33 %)
GLD $ 230.69 $ -0.57 (-0.25 %)
$ 117.84
$ 114.70
$ 105.98 x 110
$ 115.96 x 200
$ 112.74 - $ 116.83
$ 97.23 - $ 134.63
8,577,276
na
298.7B
$ 0.33
$ 21.75
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-26-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-24-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-05-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 02-26-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-08-2018 03-31-2018 10-Q
27 02-27-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 02-28-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-07-2015 03-31-2015 10-Q
39 02-27-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

methanex-merck-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Methanex, Merck And Other Big Stocks Movin...
09/09/2024 12:11:16

summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-risk-of-disease-or-death-by-half
Summit Therapeutics' Lung Cancer Candidate...
09/09/2024 12:02:45

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free sur...

why-summit-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket
Why Summit Therapeutics Shares Are Trading...
09/09/2024 10:08:36

Core News & Articles
Reported Saturday, Daiichi Sankyo And Merc...
09/09/2024 08:13:06

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck's ifinatamab deruxtecan at 12 mg/kg dose in pretreate...

whats-going-on-with-merck-shares-thursday
What's Going On With Merck Shares Thursday?
09/05/2024 18:42:49

Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceu...

Core News & Articles
Merck Canada And The Pan-Canadian Pharmace...
09/05/2024 15:22:26

Approved indications include the treatment of adult patients with von Hippel-Lindau (VHL) disease for associated non-metastatic...

merck-announces-canadian-authorization-of-winrevair-sotatercept-as-first-activin-signaling-inhibitor-therapy-for-pulmonary-arterial-hypertension-in-adults
Merck Announces Canadian Authorization Of ...
09/04/2024 19:01:17

merck-and-eyebio-launch-phase-2b3-trial-for-diabetic-macular-edema-treatment
Merck and EyeBio Launch Phase 2b/3 Trial f...
09/04/2024 10:45:19

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and EyeBio, a wholly-owned subsidiary of Merck & Co...

mercks-death-cross-vs-gileads-golden-cross-pharma-giants-diverge-on-wall-street
Merck's Death Cross Vs. Gilead's Golden Cr...
09/03/2024 20:17:53

Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging techn...

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs
Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
09/03/2024 17:35:17

mrk---analyzing-merck--cos-short-interest
(MRK) - Analyzing Merck & Co's Short Interest
09/03/2024 14:15:24

the-european-commission-has-approved-mercks-keytruda-pembrolizumab-in-combination-with-padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma-in-adults
The European Commission Has Approved Merck...
09/03/2024 10:49:52

behind-the-scenes-of-merck--cos-latest-options-trends
Behind the Scenes of Merck & Co's Latest O...
08/30/2024 20:33:19

Core News & Articles
Moderna And BioNTech Bet On Personalized C...
08/29/2024 16:01:34

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these i...

cantor-fitzgerald-reiterates-overweight-on-merck--co-maintains-155-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/29/2024 15:29:12

Cantor Fitzgerald analyst Louise Chen reiterates Merck & Co (NYSE:MRK) with a Overweight and maintains $155 price target.

merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data
Merck Pulls Plug On Two Keytruda Late-Stag...
08/29/2024 14:35:31

Merck discontinues two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, for Keytruda in lung cancer and cutaneous squamous cell car...

merck-to-discontinue-phase-3-keynote-867-trial-of-keytruda-plus-stereotactic-body-radiotherapy-for-patients-with-stage-i-or-ii-non-small-cell-lung-cancer-and-phase-3-keynote-630-trial-of-keytruda-as-adjuvant-treatment-of-patients-with-high-risk-locally-advanced-cutaneous-squamous-cell-carcinoma-following-surgery-and-radiation
Merck To Discontinue Phase 3 Keynote-867 T...
08/29/2024 10:34:09

. This decision is based on the recommendation of an independent Data Monitoring Committee (DMC), which reviewed data from a pl...

comparing-merck-amp-co-with-industry-competitors-in-pharmaceuticals-industry
Comparing Merck & Co With Industry Com...
08/28/2024 15:00:55

merck-has-initiated-shorespan-007-phase-3-trial-of-bomedemstat-for-essential-thrombocythemia-who-have-previously-not-received-cytoreductive-therapy
Merck Has Initiated Shorespan-007 Phase 3 ...
08/27/2024 10:49:46

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION